However, In patients with T2DM, oral semaglutide showed better glycemic control than placebo over 26 weeks [48]
Conclusion arGLP-1 are effective and safe for managing IWL or WR after BS, leading to significant weight loss, comorbidity improvement, and sustained %TWL
Subsequently, semaglutide (SEMA), a once-weekly injectable GLP-1 receptor agonist, was launched in 2021.1,3 Structure and mechanism of action Both LIRA and SEMA are subcutaneously administered GLP-1 receptor agonists, sharing 97% and 94% homology, respectively, with the native GLP-1 molecule
The G-site is more hydrophilic and exhibits a higher degree of sequence conservation within GST families than the H-site [42]